The global radiodermatitis market is expected to reach USD 442.1 million by 2025.
The global radiodermatitis market is expected to grow at an unprecedented rate owing to the growing prevalence of cancer patients undergoing radiation therapy. The demand for radiodermatitis treatment is also accentuated by unmet medical needs of consumers in emerging as well as developed regions. Increasing focus of government healthcare organizations for promoting awareness about available treatment products for radiodermatitisis predicted to present the market with high potential growth opportunities.
In addition, increasing R&D activities in the area of life sciences is presumed to be one of the significant factors contributing toward growth of this market. For instance, in December 2016, Mölnlycke Health Care AB entered into a licensing agreement with a Texas-based R&D company Rochal Industries. This agreement was carried out to reinforce its position as a prevention solutions firm. In addition, they have signed a joint agreement to enhance their R&D capabilities and commercialize new patented technological platforms.Other factors such as escalating number of product launches with respect to radiodermatitis treatment and increasing demand for these products are expected to boost the overall market growth.
- Stratpharma AG
- Smith & Nephew
- Molnlycke Health Care AB
- Derma Sciences Inc.
- ConvaTec Inc.
- BMG Pharma S.R.L.
Key Topics Covered:
1 Research Methodology & Scope
2 Executive Summary
3 Radiodermatitis Market Variables, Trends & Scope
4 Radiodermatitis Market: Product Estimates & Trend Analysis
5 Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis
6 Radiodermatitis Market: Regional Estimates & Trend Analysis, by Product & Distribution Channel
7 Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/research/gkpf4p/radiodermatitis